Lv6
2648 积分 2023-04-17 加入
[Expert consensus on Claudin18.2 expression testing in gastric cancer (2025 version)]
29天前
已完结
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
2个月前
已完结
The impact of claudin-18.2 expression in patients with advanced gastric cancer treated with nivolumab
2个月前
已关闭
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001)
2个月前
已完结
1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
2个月前
已关闭
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors
2个月前
已关闭
Claudin 18.2 as a novel therapeutic target
2个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
2个月前
已完结
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
3个月前
已完结
Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
3个月前
已完结
皖公网安备34019202002308
